348 related articles for article (PubMed ID: 15102786)
1. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
Johnson AH; Leke RG; Mendell NR; Shon D; Suh YJ; Bomba-Nkolo D; Tchinda V; Kouontchou S; Thuita LW; van der Wel AM; Thomas A; Stowers A; Saul A; Zhou A; Taylor DW; Quakyi IA
Infect Immun; 2004 May; 72(5):2762-71. PubMed ID: 15102786
[TBL] [Abstract][Full Text] [Related]
2. Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals.
Zhang Q; Xue X; Xu X; Wang C; Chang W; Pan W
J Clin Immunol; 2009 Jul; 29(4):454-60. PubMed ID: 19247821
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
[TBL] [Abstract][Full Text] [Related]
4. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.
Cortés A; Mellombo M; Masciantonio R; Murphy VJ; Reeder JC; Anders RF
Infect Immun; 2005 Jan; 73(1):422-30. PubMed ID: 15618180
[TBL] [Abstract][Full Text] [Related]
5. Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2.
Johnson A; Leke R; Harun L; Ginsberg C; Ngogang J; Stowers A; Saul A; Quakyi IA
Infect Immun; 2000 Apr; 68(4):2231-6. PubMed ID: 10722624
[TBL] [Abstract][Full Text] [Related]
6. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
Stanisic DI; Richards JS; McCallum FJ; Michon P; King CL; Schoepflin S; Gilson PR; Murphy VJ; Anders RF; Mueller I; Beeson JG
Infect Immun; 2009 Mar; 77(3):1165-74. PubMed ID: 19139189
[TBL] [Abstract][Full Text] [Related]
8. Host genetic polymorphisms and serological response against malaria in a selected population in Sri Lanka.
Dewasurendra RL; Jeffreys A; Gunawardena SA; Chandrasekharan NV; Rockett K; Kwiatkowski D; Karunaweera ND
Malar J; 2018 Dec; 17(1):473. PubMed ID: 30558622
[TBL] [Abstract][Full Text] [Related]
9. Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.
Ibison F; Olotu A; Muema DM; Mwacharo J; Ohuma E; Kimani D; Marsh K; Bejon P; Ndungu FM
PLoS One; 2012; 7(12):e52939. PubMed ID: 23300828
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
[TBL] [Abstract][Full Text] [Related]
11. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
[TBL] [Abstract][Full Text] [Related]
13. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
14. Associations Between Helminth Infections, Plasmodium falciparum Parasite Carriage and Antibody Responses to Sexual and Asexual Stage Malarial Antigens.
Ateba-Ngoa U; Jones S; Zinsou JF; Honkpehedji J; Adegnika AA; Agobe JC; Massinga-Loembe M; Mordmüller B; Bousema T; Yazdanbakhsh M
Am J Trop Med Hyg; 2016 Aug; 95(2):394-400. PubMed ID: 27273645
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
[TBL] [Abstract][Full Text] [Related]
16. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC; Choudhary P; de Cassan SC; Biswas S; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Hodgson SH; Duncan CJ; Hill AV; Draper SJ
Immunology; 2014 Apr; 141(4):628-44. PubMed ID: 24303947
[TBL] [Abstract][Full Text] [Related]
17. Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda.
Apio B; Nalunkuma A; Okello D; Riley E; Egwang TG
East Afr Med J; 2000 Apr; 77(4):189-93. PubMed ID: 12858901
[TBL] [Abstract][Full Text] [Related]
18. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.
Osier FH; Weedall GD; Verra F; Murungi L; Tetteh KK; Bull P; Faber BW; Remarque E; Thomas A; Marsh K; Conway DJ
Infect Immun; 2010 Nov; 78(11):4625-33. PubMed ID: 20732997
[TBL] [Abstract][Full Text] [Related]
19. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
[TBL] [Abstract][Full Text] [Related]
20. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
